Oaktree Acquisition Corp. III Life Sciences
Oaktree Acquisition Corp. III Life Sciences
Your view on OACCW
Overview
What the company does, where it operates, and who runs it.
About Oaktree Acquisition Corp. III Life Sciences
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Zaid Pardesi
- Headquarters
- 333 South Grand Avenue, Los Angeles, CA, US
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Zaid Pardesi
- Headquarters
- 333 South Grand Avenue, Los Angeles, CA, US
Oaktree Acquisition Corp. III Life Sciences presently lacks significant commercial operations. Its primary focus is on completing a business combination, which could take the form of a merger, share exchange, asset acquisition, stock purchase, reorganization, or a similar corporate transaction, with one or more entities.
The company aims to identify and acquire businesses operating in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors across North America and Europe. Incorporated in 2024, its base of operations is in Los Angeles, California.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Oaktree Acquisition Corp. III Life Sciences from FRC's valuation model, read against the market price. OACCW last traded at $0.79, 58.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Oaktree Acquisition Corp. III Life Sciences. Starting points for Oaktree Acquisition Corp. III Life Sciences: P/E 58.4, EPS $0.23, beta 0.20 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Oaktree Acquisition Corp. III Life Sciences. Oaktree Acquisition Corp. III Life Sciences does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Oaktree Acquisition Corp. III Life Sciences. Trailing twelve-month EPS for Oaktree Acquisition Corp. III Life Sciences stands at $0.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Oaktree Acquisition Corp. III Life Sciences. Oaktree Acquisition Corp. III Life Sciences has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- DRDBWRoman DBDR Acquisition Corp. IIFinancial - Conglomerates$180M
- GPATWGP-Act III Acquisition Corp.Shell Companies$275M
- LPAAWLaunch One Acquisition Corp.Shell Companies$77M
- MACIWMelar Acquisition Corp. I WarrantShell Companies$210M
- PLMKWPlum Acquisition Corp. IVShell Companies$222M
- SIMAWSIM Acquisition Corp. IShell Companies$2M
More Shell Companies companies
- ORIQWOrigin Investment Corp I Warrant.NASDAQ$1M
- OTAIStarlink Ai Acquisition Corp.NYSE$136M
- LPCVLaunchpad Cadenza Acquisition Corp I Class A Ordinary ShareNASDAQ$233M
- LPCVULaunchpad Cadenza Acquisition Corp INASDAQ$235M
- LPCVWLaunchpad Cadenza Acquisition Corp I WarrantNASDAQ$87M
- LTGJXiamen Lutong International Travel Agency Co. Ltd.OTC$17,450
- LTGRWLong Table Growth Corp. WarrantsNASDAQ$2M
- LWACLightWave Acquisition Corp.NASDAQ$313M
- LWACULightWave Acquisition Corp.NASDAQ$313M
- LWACWLightWave Acquisition Corp.NASDAQ$158M
- MACIMelar Acquisition Corp. INASDAQ$217M
- MACIUMelar Acquisition Corp. INASDAQ$226M
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Oaktree Acquisition Corp. III Life Sciences executives and directors. Shares of Oaktree Acquisition Corp. III Life Sciences have traded between $0.82 and $1.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Oaktree Acquisition Corp. III Life Sciences. Coverage tracks Oaktree Acquisition Corp. III Life Sciences within Shell Companies (Financial Services). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Oaktree Acquisition Corp. III Life Sciences.